Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU12-157

A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • N.M. Hahn, T.J. Bivalacqua, A. Ross, G.J. Netto, J.C. Park, T.A. Masterson, M.O. Koch, R. Bihrle, R. Foster, T. A. Gardner, L. Cheng, D.R. Jones, K. McElyea, G. Sandusky, Z. Liu, S.A. Turner, G.J. Tsongalis, E. R. Plimack, R. E. Greenberg, D. M. Geynisman. Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157. Accepted as a poster session at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr 4526). See abstract.